CRMD
CorMedix Inc.
Healthcare · Biotechnology · NGM
$8.36
Data: 2026-06-06
✓ ETHICAL PASS

STRONG MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$656M
Total market value of the company
Trailing P/E
3.85
Very cheap relative to earnings
Forward P/E
23.89
Based on estimated future earnings — lower means cheaper
Rev Growth
+226.1%
Year-over-year revenue change
Profit Margin
45.2%
How much profit the company keeps from each dollar of revenue
ROE
65.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$15.00
+79% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 6 analysts covering this stock
About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

https://cormedix.com

Country: United States Employees: 191 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
23.9% PASS
Debt must be below 33% of total assets
Cash Ratio
23.9% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Fair Value Est.
$21.75
What our model estimates this business is worth per share
Margin of Safety
61.6%
Deep discount to fair value — significant undervaluation
Rating
STRONG OPPORTUNITY
Overall assessment combining ethics, valuation, and quality
Percentile
98.6th
Ranks in the top 1% of our 13,571 screened universe
Ethical Score
81.9
Valuation Score
88.0
Quality Score
70.0
Combined
77.2

Trading at $8 against a fair value of $22, a 65% discount. Strong competitive moat. 45% profit margins. Passes all ethical screens. Ranks better than 99% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.678
Good returns relative to risk taken
Kelly Fraction
0.0510
Suggested allocation is meaningful — the edge justifies a position
Calmar Ratio
0.392
Drawdown risk outweighs the returns — higher risk profile
Annual Return
24.4%
Historical annualised return based on price data
Max Drawdown
-62.3%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
74
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.47
Moves slightly more than the broader market
52W High
$17.43
52% below the year high
52W Low
$6.13
36% above the year low
Avg Volume
1,334,407
Average daily shares traded — higher means easier to buy and sell
Short Ratio
12.7
Days it would take all short sellers to cover — higher means more crowded
Short % Float
20.1%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$2.17
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
33.73
Heavy leverage — higher financial risk if revenues decline
Current Ratio
2.98
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
2.59
Like current ratio but excludes inventory — stricter test
Gross Margin
91.9%
Revenue left after cost of goods — higher means pricing power
Operating Margin
50.0%
Profit from core operations before interest and tax
Free Cash Flow
$120M
Positive — the business generates more cash than it spends
Revenue (TTM)
$400M
Total revenue over the last 12 months
Net Income
$180M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
6
Target High
$19.00
Target Median
$15.00
Target Low
$13.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-02-04 TODISCO JOSEPH Chief Executive Officer 77,156 —
2026-02-04 ZELNICK KAUFMAN BETH Officer 36,006 —
2026-02-04 HURLBURT ELIZABETH Chief Operating Officer 36,006 —
2026-01-26 LEFKOWITZ STEVEN W Director 30,453 —
2026-01-26 DUNTON ALAN WILLIAM Director 30,453 —
2026-01-26 STEWART ROBERT A Director 30,453 —
2026-01-26 DILLIONE JANET M Director 30,453 —
2026-01-26 KAPLAN MYRON Director 30,453 —
2026-01-26 DUNCAN GREGORY SCOTT Director 30,453 —
2026-01-23 TODISCO JOSEPH Chief Executive Officer 225,900 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-06

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.